+57.4%
INTC vs MRNA
+945.0%
-887.7%
-58.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -3.8% | +13.1% | -16.9% | -4.1% |
| 7D | -39.0% | +20.6% | -59.6% | -39.3% |
| 30D | -49.8% | +27.1% | -77.0% | -50.1% |
| 3M | -42.2% | +353.4% | -395.6% | -45.9% |
| 6M | -39.2% | +446.3% | -485.4% | -47.6% |
| YTD | +57.9% | +776.2% | -718.2% | +17.3% |
| 1Y | +57.4% | +987.9% | -930.6% | +6.8% |
| All | +57.4% | +945.0% | -887.7% | +6.8% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling